We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Benevolent AI (BAI) EUR1 A

Sell:€0.30 Buy:€0.57 Change: €0.27 (36.99%)
Market closed |  Prices as at close on 11 December 2024 | Switch to live prices |
Sell:€0.30
Buy:€0.57
Change: €0.27 (36.99%)
Market closed |  Prices as at close on 11 December 2024 | Switch to live prices |
Sell:€0.30
Buy:€0.57
Change: €0.27 (36.99%)
Market closed |  Prices as at close on 11 December 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

BenevolentAI SA is engaged in creating and applying artificial intelligence (AI) and machine learning in drug discovery. The Company designs its technology to enable scientists to better understand the development of disease mechanisms, discover drug targets and make decisions. It serves patients by leveraging its proprietary and validated Benevolent Platform that integrates AI and science to uncover new biology, predict novel targets and develop drugs for complex diseases. The Benevolent Platform integrates technology, processes, and humans for faster research and development success. Its pipeline includes BEN-8744, BEN-28010, BEN-34712, Parkinson's disease, and Fibrosis. BEN-8744 is developed for the treatment of an ulcerative colitis. The Company provides scientists with a view of disease biology by integrating across all the domains and diverse data types, including omics, molecules, experimental data, literature, pathology, and biological systems.

Contact details

Address:
4-8 Maple Street
LONDON
W1T 5HD
United Kingdom
Telephone:
+44 (20) 37819360
Website:
https://www.benevolent.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BAI
ISIN:
LU2355630455
Market cap:
€65.90 million
Shares in issue:
121.94 million
Sector:
Pharmaceuticals
Exchange:
Euronext Amsterdam
Country:
Unclassified
Currency:
Euro
Indices:
n/a

Key personnel

  • Kenneth Mulvany
    Executive Chairman of the Board
  • Peter Allen
    Deputy Chairman of the Board
  • Ivan Griffin
    Co-Founder, Chief Operating Officer
  • Anna Fullerton-batten
    Chief People Officer
  • Daniel Neil
    Chief Technology Officer
  • Will Scrimshaw
    General Counsel, Company Secretary
  • Michael Brennan
    Chief Strategy and Financial Officer
  • Christina Busmalis
    Chief Revenue Officer
  • Anne Phelan
    Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.